Acute Migraine With Or Without Aura Therapeutics
1. Ubrelvy patent expiration
Treatment: Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without au...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(6 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US12329750 | ABBVIE | NA |
Dec, 2041
(15 years from now) | |
| US12194030 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12220408 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US12070450 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12458632 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US12168004 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US11925709 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12458633 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12310953 | ABBVIE | Pharmaceutical formulations for the treatment of migraine |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
